What’s you missed in 2026
Accelerate Neuropsychiatric Drug Development with Precision, Translation & Regulatory‑Ready Innovation
Uniting 150+ global leaders across pharma, biotech, academia, clinical research, regulatory affairs, investment, and patient advocacy, the 9th Neuropsychiatric Drug Development Summit served as the industry's most focused forum for advancing safer, more effective, and biologically grounded mental health therapeutics. As persistent challenges including placebo response, patient heterogeneity, and Phase II/III failure continued to stall promising assets, the meeting provided a platform to sharpen translational decision‑making and align the field around precision‑driven solutions.
With 40+ expert speakers and a deeply technical program spanning discovery biology through late‑stage clinical execution and regulatory strategy, attendees gained critical insights into precision psychiatry frameworks, EEG and sleep biomarkers, neuroplasticity‑driven mechanisms, patient‑selection strategies, and approvable endpoints, with a clear focus on derisking development and delivering meaningful patient impact.
Agenda Focus
This year’s agenda dived into neuroplastogens and psychedelics, ketamine derived and non hallucinogenic rapid acting therapeutics, muscarinic M1/M4 innovation, orexin and sleep wake biology, and emerging neurometabolic and dopaminergic strategies, alongside the translational tools required to make these mechanisms succeed clinically.
Attendees explored EEG and sleep EEG standardization, AI‑enabled signal detection, speech and digital biomarkers, genetics‑anchored models, and multimodal endpoint strategies to improve patient stratification and overcome the Phase II/III roadblock.
Dedicated EEG and Clinical & Regulatory tracks addressed how biomarkers, novel COAs, cognition, functional quality of life and real‑world measures could be operationalised, validated, and aligned with evolving FDA and EMA expectations.
Industry leaders from AbbVie, Bristol Myers Squibb, Johnson & Johnson, Lundbeck, Neumora, Otsuka, COMPASS Pathways, Delix Therapeutics, MapLight Therapeutics, Gilgamesh, Alkermes, and more shared hard‑won lessons from recent successes and failures, alongside enabling perspectives from CROs, AI and biomarker technology partners, and clinical experts. Patient‑centred voices and real‑world implementation insights ensured discussions remained grounded in clinical meaningfulness, scalability, and commercial viability.
Together, the Summit delivered the strategic clarity, scientific rigour, and collaborative momentum required to unlock the next era of precision neuropsychiatric drug development.
Key Features in 2026:
EEG Focus Day
EEG Focus Day Returns with new insights in standardization predictivity, AI & utility, and wake /sleep EEG
Expanded Investment Insights: Pharma BD & VC Panel
Explore the Catalysts Driving Deal-Making Momentum in Neuropsychiatry & Discover What Investors are Seeking from the Next Wave of Readouts
More Regulatory Content than Ever Before
8+ New Presenting Companies Including
What you missed in 2026
From Symptoms to Biology: Advancing Precision Psychiatry
Explore how EEG, genetics, molecular biomarkers, and AI‑enabled tools are shifting psychiatry toward biologically grounded development and precision patient stratification, with insights from AbbVie, Lundbeck, Neumora, Alto Neuroscience, COMPASS Pathways, and Otsuka.
Modernizing Preclinical Models to Improve Translational Predictivity
Learn how next‑generation, genetics‑anchored models and circuit‑level readouts are replacing legacy behavioural assays to improve human predictivity, featuring leaders from Otsuka, Broad Institute, Alkermes, Neurosterix, and XYLO Therapeutics .
Overcoming the Phase II/III Roadblock in Neuropsychiatry
Unpack hard‑won lessons from recent late‑stage successes and failures to tackle placebo response, trial heterogeneity, endpoint sensitivity, and global execution challenges, with pharma and biotech perspectives from Lundbeck, AbbVie, Neumora, Boehringer Ingelheim, and Johnson & Johnson.
Redefining Endpoints: Digital, EEG & Novel COAs for Regulatory‑Ready Trials
Examine how EEG, sleep biomarkers, speech analytics, digital endpoints, and new COAs are reshaping signal detection and regulatory engagement, with case studies from Alto Neuroscience, Boehringer Ingelheim, COMPASS Pathways, Neurocrine Biosciences, Biogen, and Transpharmation.
Where Science Meets Strategy: Investment, Deal‑Making & Partnering in Neuropsychiatry
Hear directly from pharma, biotech, and investors on how capital is flowing into neuroplastogens, muscarinics, psychedelics, and precision CNS platforms, with participation from AbbVie, Bristol Myers Squibb, MapLight Therapeutics, Gilgamesh Pharmaceuticals, Novo Holdings, Vida Ventures, Stifel, and Cowen.
Harnessing Neuroplasticity & Circuit Biology to Unlock Next‑Generation Therapeutics
Dive into the mechanistic science behind rapid‑acting antidepressants, psychedelics, ketamine‑derived agents, and non‑hallucinogenic neuroplastogens, with translational and clinical insights from COMPASS Pathways, Seaport Therapeutics, Gilgamesh Pharmaceuticals, Definium Therapeutics, Lundbeck, and University‑industry collaborators.
Explore the 2026 Full Event Guide
- 46+ World Class Speakers with Cutting Edge Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Content Spanning Discovery to Access for the Whole Team
Attending Companies Included
Explore the Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 35+ expert speakers shaping the future of psychiatric R&D
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider in neuropsychiatric and neurodevelopment research
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and regulatory voices driving real-world adoption